Laurus Labs Ltd – ₹47,500 Cr Market Cap with a 93x P/E: Pharma Darling or Just Overdosed on Valuations?
1. At a Glance
Laurus Labs, the Vizag-based pharma poster child, went from being the global chemist for HIV drugs to everyone’s favorite CDMO outsourcing partner. Today, it’s trading at a nosebleed 93x P/E while posting single-digit ROE. Investors clearly think Laurus is the next Tesla of APIs—except, instead of cars, it makes anti-retrovirals and oncology molecules. Current price ₹881, market cap ₹47,540 Cr, and a one-year return of 83%. Basically, this is pharma’s version of Maggi noodles—cheap to make, addictive to eat, but you’re paying restaurant rates.
2. Introduction
Founded in 2005, Laurus Labs has grown from a chemistry shop into a fully integrated pharma-biotech-CDMO player. With 6,500+ employees, 1,000+ scientists, 14 plants, and approvals from USFDA to TGA, it’s a legit multinational operation.
The story so far:
First innings: APIs, mainly HIV and oncology.
Second innings: Finished doses (ARVs, diabetes, cardio).
Third innings: CDMO contracts with Big Pharma (the “wedding planner” model).
Fourth innings: Laurus Bio—fermentation, proteins, and cultured meat (yes, chicken grown in a lab, not in a coop).
The company is pumping ₹3,000 Cr+ into capex, especially in CDMO and biotech, while shuffling its ARV business to higher-margin lanes. Investors are loving the pivot—share price has doubled in a year—but the balance sheet is groaning with debt, and margins look more like diet khichdi than biryani.
Question for you: Are we looking at the next Divi’s Labs in making, or just a hyped-up midcap with biotech buzzwords?
3. Business Model – WTF Do They Even Do?
APIs (46% revenue): Laurus is like the Reliance Jio of ARV APIs—everyone’s using it, but margins are wafer-thin. They’ve also got onco APIs and steroids, but ARVs remain the bread and butter.
FDF (27% revenue): Oral solids—HIV, diabetes, cardiovascular. This is Laurus trying to be Cipla-lite, but export-led.
CDMO (24% revenue): The money-spinner. Contract synthesis for US/EU/Japan innovators. 70+ projects in pipeline, 10 already commercial. This is where Laurus wants to transform into a chemistry concierge.
Biotech (3% revenue): Laurus Bio is the hipster unit—fermentation, nutraceuticals, cosmeceuticals, cultured meat proteins. Backed by PE investors, scaling up to 400 KL fermentation by 2026.
Basically, Laurus is juggling HIV pills for Africa, diabetes drugs for the US, and lab-grown chicken protein for hipsters in California. Diversification level: Baba Ramdev trying stand-up comedy.
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue (₹Cr)
1,570
1,195
1,720
31.4%
-8.7%
EBITDA (₹Cr)
382
171
421
123.4%
-9.3%
PAT (₹Cr)
163
13
233
1,203%
-30.0%
EPS (₹)
3.0
0.2
4.3
1,200%
-30.0%
Commentary: YoY numbers look like Virat Kohli in form; QoQ looks like Rohit Sharma after biryani. EPS annualized = ₹12, P/E shoots above 70x, but Screener shows trailing P/E ~93x. Investors clearly living in the future.
